MedTrace Logo

Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer

NCT00433095 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2011-03-14

No results posted yet for this study

Summary

1st-line treatment of HER2/neu overexpressing breast cancer

Conditions

  • Carcinoma Breast Stage IV

Interventions

DRUG

Navelbine

DRUG

Herceptin

DRUG

Navelbine (oraly)

Sponsors & Collaborators

  • Pierre Fabre Laboratories

    collaborator INDUSTRY

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Volker Heinemann, PhD, MD · University of Munich - Klinikum Grosshadern

  • Hans-Joachim Stemmler, PhD, MD · University of Munich - Klinikum Grosshadern

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00433095 on ClinicalTrials.gov